PortalPublikationenMaintenance of response in moderate-to-severe psoriasis afte...

Maintenance of response in moderate-to-severe psoriasis after withdrawal of the interleukin (IL)-17A and IL-17F nanobody sonelokimab: is there a role for IL-17F in disease reoccurrence?

Standard

Maintenance of response in moderate-to-severe psoriasis after withdrawal of the interleukin (IL)-17A and IL-17F nanobody sonelokimab: is there a role for IL-17F in disease reoccurrence? / Reich, Kristian; Cullen, Eva; Weinberg, Mark.

in: BRIT J DERMATOL, Jahrgang 187, Nr. 4, 10.2022, S. 591-593.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › Andere (Vorworte u.ä.) › Forschung

Harvard

Reich, K, Cullen, E & Weinberg, M 2022, 'Maintenance of response in moderate-to-severe psoriasis after withdrawal of the interleukin (IL)-17A and IL-17F nanobody sonelokimab: is there a role for IL-17F in disease reoccurrence?', BRIT J DERMATOL, Jg. 187, Nr. 4, S. 591-593. https://doi.org/10.1111/bjd.21617

APA

Reich, K., Cullen, E., & Weinberg, M. (2022). Maintenance of response in moderate-to-severe psoriasis after withdrawal of the interleukin (IL)-17A and IL-17F nanobody sonelokimab: is there a role for IL-17F in disease reoccurrence? BRIT J DERMATOL, 187(4), 591-593. https://doi.org/10.1111/bjd.21617

Vancouver

Reich K, Cullen E, Weinberg M. Maintenance of response in moderate-to-severe psoriasis after withdrawal of the interleukin (IL)-17A and IL-17F nanobody sonelokimab: is there a role for IL-17F in disease reoccurrence? BRIT J DERMATOL. 2022 Okt;187(4):591-593. https://doi.org/10.1111/bjd.21617

Bibtex

@article{88a83279f0604db1b10e533696e5e44e,
title = "Maintenance of response in moderate-to-severe psoriasis after withdrawal of the interleukin (IL)-17A and IL-17F nanobody sonelokimab: is there a role for IL-17F in disease reoccurrence?",
keywords = "Antibodies, Monoclonal, Humans, Immunologic Tests, Interleukin-17, Psoriasis/drug therapy",
author = "Kristian Reich and Eva Cullen and Mark Weinberg",
year = "2022",
month = oct,
doi = "10.1111/bjd.21617",
language = "English",
volume = "187",
pages = "591--593",
journal = "BRIT J DERMATOL",
issn = "0007-0963",
publisher = "Wiley-Blackwell",
number = "4",

}

RIS

TY - JOUR

T1 - Maintenance of response in moderate-to-severe psoriasis after withdrawal of the interleukin (IL)-17A and IL-17F nanobody sonelokimab: is there a role for IL-17F in disease reoccurrence?

AU - Reich, Kristian

AU - Cullen, Eva

AU - Weinberg, Mark

PY - 2022/10

Y1 - 2022/10

KW - Antibodies, Monoclonal

KW - Humans

KW - Immunologic Tests

KW - Interleukin-17

KW - Psoriasis/drug therapy

U2 - 10.1111/bjd.21617

DO - 10.1111/bjd.21617

M3 - Other (editorial matter etc.)

C2 - 35442535

VL - 187

SP - 591

EP - 593

JO - BRIT J DERMATOL

JF - BRIT J DERMATOL

SN - 0007-0963

IS - 4

ER -